These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

284 related articles for article (PubMed ID: 33106832)

  • 1. [Structure of SARS-CoV-2 and treatment of COVID-19].
    Chen HX; Chen ZH; Shen HH
    Sheng Li Xue Bao; 2020 Oct; 72(5):617-630. PubMed ID: 33106832
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Searching therapeutic strategy of new coronavirus pneumonia from angiotensin-converting enzyme 2: the target of COVID-19 and SARS-CoV.
    Li SR; Tang ZJ; Li ZH; Liu X
    Eur J Clin Microbiol Infect Dis; 2020 Jun; 39(6):1021-1026. PubMed ID: 32285293
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Soluble angiotensin-converting enzyme 2: a potential approach for coronavirus infection therapy?
    Batlle D; Wysocki J; Satchell K
    Clin Sci (Lond); 2020 Mar; 134(5):543-545. PubMed ID: 32167153
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Innate Immune Signaling and Proteolytic Pathways in the Resolution or Exacerbation of SARS-CoV-2 in Covid-19: Key Therapeutic Targets?
    Sallenave JM; Guillot L
    Front Immunol; 2020; 11():1229. PubMed ID: 32574272
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Outcomes in Patients with COVID-19 Infection Taking ACEI/ARB.
    Rico-Mesa JS; White A; Anderson AS
    Curr Cardiol Rep; 2020 Apr; 22(5):31. PubMed ID: 32291526
    [TBL] [Abstract][Full Text] [Related]  

  • 6. A global treatments for coronaviruses including COVID-19.
    Yousefi B; Valizadeh S; Ghaffari H; Vahedi A; Karbalaei M; Eslami M
    J Cell Physiol; 2020 Dec; 235(12):9133-9142. PubMed ID: 32394467
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Harnessing the immune system to overcome cytokine storm and reduce viral load in COVID-19: a review of the phases of illness and therapeutic agents.
    Khadke S; Ahmed N; Ahmed N; Ratts R; Raju S; Gallogly M; de Lima M; Sohail MR
    Virol J; 2020 Oct; 17(1):154. PubMed ID: 33059711
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Hazards of the Cytokine Storm and Cytokine-Targeted Therapy in Patients With COVID-19: Review.
    Quirch M; Lee J; Rehman S
    J Med Internet Res; 2020 Aug; 22(8):e20193. PubMed ID: 32707537
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Coronavirus disease 2019 (COVID-19) and the renin-angiotensin system: A closer look at angiotensin-converting enzyme 2 (ACE2).
    Zemlin AE; Wiese OJ
    Ann Clin Biochem; 2020 Sep; 57(5):339-350. PubMed ID: 32369402
    [TBL] [Abstract][Full Text] [Related]  

  • 10. The origin, transmission and clinical therapies on coronavirus disease 2019 (COVID-19) outbreak - an update on the status.
    Guo YR; Cao QD; Hong ZS; Tan YY; Chen SD; Jin HJ; Tan KS; Wang DY; Yan Y
    Mil Med Res; 2020 Mar; 7(1):11. PubMed ID: 32169119
    [TBL] [Abstract][Full Text] [Related]  

  • 11. [Characteristics of SARS-CoV-2 and potential pharmacological treatment].
    Pawlik L; Śpiołek E; Fichna J; Tarasiuk A
    Postepy Biochem; 2020 May; 66(2):83-90. PubMed ID: 32700510
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2): An overview of viral structure and host response.
    Astuti I; Ysrafil
    Diabetes Metab Syndr; 2020; 14(4):407-412. PubMed ID: 32335367
    [TBL] [Abstract][Full Text] [Related]  

  • 13. The Immune Response and Immunopathology of COVID-19.
    Mortaz E; Tabarsi P; Varahram M; Folkerts G; Adcock IM
    Front Immunol; 2020; 11():2037. PubMed ID: 32983152
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Biological, clinical and epidemiological features of COVID-19, SARS and MERS and AutoDock simulation of ACE2.
    Zhang XY; Huang HJ; Zhuang DL; Nasser MI; Yang MH; Zhu P; Zhao MY
    Infect Dis Poverty; 2020 Jul; 9(1):99. PubMed ID: 32690096
    [TBL] [Abstract][Full Text] [Related]  

  • 15. The novel zoonotic COVID-19 pandemic: An expected global health concern.
    Contini C; Di Nuzzo M; Barp N; Bonazza A; De Giorgio R; Tognon M; Rubino S
    J Infect Dev Ctries; 2020 Mar; 14(3):254-264. PubMed ID: 32235085
    [TBL] [Abstract][Full Text] [Related]  

  • 16. What would Sérgio Ferreira say to your physician in this war against COVID-19: How about kallikrein/kinin system?
    Nicolau LAD; Magalhães PJC; Vale ML
    Med Hypotheses; 2020 Oct; 143():109886. PubMed ID: 32504925
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Inhaled modified angiotensin converting enzyme 2 (ACE2) as a decoy to mitigate SARS-CoV-2 infection.
    Ameratunga R; Lehnert K; Leung E; Comoletti D; Snell R; Woon ST; Abbott W; Mears E; Steele R; McKee J; Muscroft-Taylor A; Ameratunga S; Medlicott N; Das S; Rolleston W; Quiñones-Mateu M; Petousis-Harris H; Jordan A
    N Z Med J; 2020 May; 133(1515):112-118. PubMed ID: 32438383
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Strategies for Targeting SARS CoV-2: Small Molecule Inhibitors-The Current Status.
    Beeraka NM; Sadhu SP; Madhunapantula SV; Rao Pragada R; Svistunov AA; Nikolenko VN; Mikhaleva LM; Aliev G
    Front Immunol; 2020; 11():552925. PubMed ID: 33072093
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Angiotensin-converting enzyme 2: The old door for new severe acute respiratory syndrome coronavirus 2 infection.
    Tan HW; Xu YM; Lau ATY
    Rev Med Virol; 2020 Sep; 30(5):e2122. PubMed ID: 32602627
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Why COVID-19 Transmission Is More Efficient and Aggressive Than Viral Transmission in Previous Coronavirus Epidemics?
    Elrashdy F; Redwan EM; Uversky VN
    Biomolecules; 2020 Sep; 10(9):. PubMed ID: 32933047
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 15.